Clinical Trial ECOGHNE1305


Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

Principal Investigator(s)

Jill Gilbert


  • Protocol No. ECOGHNE1305
  • Open Date: 03/04/2009
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To compare the overall survival of patients with recurrent or metastatic head and neck cancer treated with standard cisplatin-based chemotherapy with or without bevacizumab.
  • Disease Sites: Head/Neck
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: 5-FU (Fluorouracil); Avastin; Bevacizumab; Carboplatin; Cisplatin; Docetaxel; Docetaxel (Taxotere)
  • Participating Institutions: Vanderbilt University; Univ of Florida - Gainesville; Erlanger Health System
  • National Clinical Trial ID: NCT00588770
  • Secondary Protocol No: E1305



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.